ALK and pneumonitis: On comparing different second‐generation ALK TKIs, patients who were administered brigatinib (3.06%, 95% CI: 1.28%–5.41%) had a higher risk of high‐grade pneumonitis than those administered ceritinib (1.18%, 95% CI: 0.15%–2.80%) and alectinib (1.22%, 95% CI: 0.16%–2.98%) (Table 3).